Showing 2831-2840 of 5771 results for "".
- First Atropine Eye Drop to Slow Myopia Progression in Children Approved in Indiahttps://modernod.com/news/first-atropine-eye-drop-to-slow-myopia-progression-in-children-approved-in-india/2482750/Entod Pharmaceuticals announced it has received marketing authorisation from the Central Drugs Standard Control Organisation (CDSCO) for the first 0.05% atropine eye drops (Myatro XL) developed to slow the progression of myopia in children age 6 to 12. This milestone foll
- MicroSurgical Technology (MST) to Discuss Advances in Vitrectomy Technology at ASCRShttps://modernod.com/news/microsurgical-technology-mst-to-discuss-advances-in-vitrectomy-technology-at-ascrs/2482749/MicroSurgical Technology (MST) announced it will share research during two presentations on the Vista 1-Step novel vitrectomy probe at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 25-28. The
- Sight Sciences Launches OMNI Edge Surgical System at ASCRShttps://modernod.com/news/sight-sciences-to-debut-omni-edge-surgical-system-at-ascrs/2482748/Sight Sciences announced the expansion of the OMNI product family by launching the OMNI Edge Surgical System. The new technology will debut at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, taking place April 25–27 in Los Angeles.<
- FDA Denies Regeneron's BLA for Extended Dosing Intervals for Eylea HDhttps://modernod.com/news/fda-denies-regenerons-bla-for-extended-dosing-intervals-for-eylea-hd/2482747/Regeneron announced that the FDA has issued a complete response letter (CRL) regarding the supplemental Biologics License Application (sBLA) for the addition of extended dosing intervals (up to every 24 weeks) for Eylea HD (aflibercept) Injection 8 mg across all approved indication
- Neurotech Appoints Beth Marsh as Chief Commercial Officerhttps://modernod.com/news/neurotech-appoints-beth-marsh-as-chief-commercial-officer/2482746/Neurotech Pharmaceuticals announced the appointment of Beth Marsh as Chief Commercial Officer, effective April 28, 2025. In this role, Ms. Marsh will lead the commercial organization, including preparing for the US launch of Encelto (revakinagene taroretcel-lwey), the first and onl
- Bausch + Lomb Recycles Over 625,000 Pounds of Eye Care Materialshttps://modernod.com/news/bausch-lomb-recycles-over-625000-pounds-of-eye-care-materials/2482745/Bausch + Lomb announced a sustainability milestone: its 'ONE by ONE' and 'Biotrue Eye Care' recycling programs have collectively diverted more than 103 million units, or 625,026 pounds, of used contact lenses and eye care materials fr
- Alcon Showcases Five Innovations Across Multiple Specialty Areas at ASCRS 2025https://modernod.com/news/alcon-showcases-five-innovations-across-multiple-specialty-areas-at-ascrs-2025/2482744/Alcon announced its lineup of new product offerings at the 2025 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, April 25-28, in Los Angeles. This year’s event will feature Alcon’s most recent product introductions across specialty areas rangi
- FDA Priority Review Accepted for Eylea HD for Both the Treatment of RVO and for Monthly Dosing in Approved Indicationshttps://modernod.com/news/fda-priority-review-accepted-for-eylea-hd-for-both-the-treatment-of-rvo-and-for-monthly-dosing-in-approved-indications/2482741/Regeneron announced that the FDA has accepted for Priority Review the supplemental Biologics License Application (sBLA) for Eylea HD (aflibercept) Injection 8 mg. The sBLA seeks approval for Eylea HD for both the treatment of macular edema following retinal vein occlusion (RVO
- Applications Being Accepted for the 2025 Ramin Tadayoni Awardhttps://modernod.com/news/applications-being-accepted-for-the-2025-ramin-tadayoni-award/2482740/Oculis, in collaboration with EURETINA, announced that applications are now being accepted for the 2025 Ramin Tadayoni Award. The Ramin Tadayoni Award continues its legacy through EURETINA and has been supported by Oculis as a lasting tribute
- MST Enters Strategic Partnership with Mani to Distribute Ophthalmic Surgical Blade Portfolio in the UShttps://modernod.com/news/microsurgical-technology-mst-enters-strategic-partnership-with-mani-to-distribute-ophthalmic-surgical-blade-portfolio-in-the-us/2482739/Microsurgical Technology (MST) announced a strategic partnership with Mani Inc. under which MST will serve as a distributor of Mani’s ophthalmic surgical blade portfolio in the United States. The deal is supported by the establishment of Mani Medical America, the US